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Abstract
Cellular prion protein (PrP
C) inhibits N-Methyl-D-Aspartate (NMDA) receptors. Since NMDA receptors play an
important role in the transmission of pain signals in the dorsal horn of spinal cord, we thus wanted to determine if
PrP
C null mice show a reduced threshold for various pain behaviours.
We compared nociceptive thresholds between wild type and PrP
C null mice in models of inflammatory and
neuropathic pain, in the presence and the absence of a NMDA receptor antagonist. 2-3 months old male PrP
C null
mice exhibited an MK-801 sensitive decrease in the paw withdrawal threshold in response both mechanical and
thermal stimuli. PrP
C null mice also exhibited significantly longer licking/biting time during both the first and
second phases of formalin-induced inflammation of the paw, which was again prevented by treatment of the mice
with MK-801, and responded more strongly to glutamate injection into the paw. Compared to wild type animals,
PrP
C null mice also exhibited a significantly greater nociceptive response (licking/biting) after intrathecal injection
of NMDA. Sciatic nerve ligation resulted in MK-801 sensitive neuropathic pain in wild-type mice, but did not further
augment the basal increase in pain behaviour observed in the null mice, suggesting that mice lacking PrP
C may
already be in a state of tonic central sensitization. Altogether, our data indicate that PrP
C exerts a critical role in
modulating nociceptive transmission at the spinal cord level, and fit with the concept of NMDA receptor
hyperfunction in the absence of PrP
C.
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Background
The dorsal horn of spinal cord is an important site for
pain transmission and modulation of incoming nocicep-
tive information arriving from peripheral nociceptors
[1,2]. Glutamate is the key neurotransmitter released by
the primary afferent fibers [3,4] and plays an important
role in nociceptor sensitization and in the modulation of
allodynia [5]. Glutamate receptors (GluRs) such as N-
methyl-D-aspartate (NMDA) receptors contribute in
various ways to pain induction, transmission and control
[5-7]. Consequently, NMDA receptor inhibitors exhibit
antinociceptive and analgesic effects in rodents [8,9] as
well in humans [10], however, their clinical use for the
treatment of pain has been hampered by their CNS
side-effects [11,12]. For this reason, strategies such as
src interfering peptides have been proposed as ways to
interfere with NMDAR hyperactivity in the pain path-
way without affecting basal NMDA receptor function
[13].
NMDA receptors are regulated by a plethora of cellu-
lar signaling pathways that could potentially be targeted
for therapeutic intervetion [14]. Along these lines, our
laboratory has recently shown [15] that NMDA receptor
activity in mouse hippocampal neurons is regulated by
cellular prion protein (PrP
c). Specifically, NMDA recep-
tors expressed in mice lacking PrP
C show slowed cur-
rent decay kinetics, and spontaneous synaptic NMDA
currents in pyramidal neurons displayed increased cur-
rent amplitude [15]. We subsequently showed that PrP
C
protects from depressive like behavior by tonically inhi-
biting NMDA receptor activity [16], thus suggesting that
the altered NMDA currents in PrP
C null mice are asso-
ciated with a clear behavioral phenotype. Given the
important role of NMDA receptors in the afferent pain
pathway, we hypothesized that absence of PrP
C may
give rise to pain hypersensitivity. Here, we show that
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C null mice exhibit a decreased nociceptive thresh-
old, both under basal conditions, as well as in models of
inflammatory and neuropathic pain. These effects were
reversed by treatment of the animals with the NMDA
receptor antagonist MK-801, thus implicating NMDA
receptor dysregulation in the observed pain phenotype.
Results




To determine if PrP
C plays a role in the transmission
of pain signals, we compared nociception in wild type
and PrP
C null mice. Paw withdrawal thresholds in
response to mechanical and thermal stimuli were mea-
sured using the Dynamic Plantar Aesthesiometer
(DPA) and Plantar Test devices, respectively. As shown
in Figure 1, a blinded time-course analysis showed that
PrP
C null mice exhibit significantly decreased mechani-
c a la n dt h e r m a lw i t h d r a w a lt hresholds when compared
to the wild-type group. Specifically, mechanical thresh-
olds were significantly different in 2 month old animals
(Figure 1A) whereas differences in thermal threshold
appeared became statistically significant at an age of 3
months (Figure 1B). These differences were then main-
tained up to an age of 5 months, after which point the
experiment was terminated. To ascertain whether this
effect was mediated by spinal NMDA receptor hyper-
function, we intrathecally (i.t.) delivered 3 nmol of the
NMDA receptor blocker MK-801 10 minutes prior to
assessing mechanical withdrawal threshold. As shown
in Figure 1C, MK-801 reversed the decreased mechani-
cal withdrawal threshold of PrP
C null mice. Two-way
ANOVA revealed a significant difference of genotype
[F(2,57) = 5.6 P < 0.05] and genotype X-treatment
interaction [F(1,43 = 5.5 P < 0.05)]. Altogether, these
data indicate that the PrP
C inhibits nociceptive signal-
ling through an NMDA receptor dependent
mechanism.
Figure 1 Mechanical and thermal withdrawal threshold of PrP
+/+ and PrP
-/- mice. Time course of basal mechanical (panel A) and thermal
(panel B) nociceptive threshold of wild type or PrP
c null mice as a function of the age of the animal. (C) Effect of pretreatment of 3 months old
mice with MK-801 (3 nmol/i.t.) on mechanical withdrawal threshold. Each point or column represents the mean ± S.E.M. (n = 5-6). *P < 0.05, **P
< 0.01.
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Next we used the formalin test to determine if PrP
C null
mice display increased sensitivity to acute nociceptive
stimulation. As shown in Figure 2, PrP
C null mice
exhibited significantly elevated licking/biting time in
both the first (Figure 2A) and second (Figure 2B) phases
of nociception induced by formalin (0.7% or 1.25%).
Treatment of mice with MK-801 (3 nmol/i.t., 10 min
prior to testing) resulted in a significant reduction of
the nociceptive behaviour of PrP
C-/- null mice for both
the first (Figure 2C) and second (Figure 2D) phases of
formalin-induced nociception. Two-way ANOVA
revealed a significant difference of genotype [F(2,31) =
3.4, P < 0.05] and genotype X-treatment interaction [F
(6,52) = 3.4, P < 0.05)] for the earlier (first) phase, and
for the second phase (genotype [F(11,80) = 4.3, P <
0.05] and genotype X-treatment interaction [F(16,35) =
3.4, P < 0.001)]).
We also directly injected glutamate (3 μmol or 10
μmol) into the paws of wild type and null mice, and
determined the time that the animals spent licking and
biting over a 15 minute time course. As shown in Figure
2E, the higher dose of glutamate resulted in a signifi-
cantly greater increase in response time compared to
wild type animals.
Nociceptive response of PrP
+/+ and PrP
-/- mice in
response to NMDA treatment
To further investigate the involvement of spinal NMDA
receptors in the decreased nociceptive threshold of PrP
C
null mice we directly activated these receptors via i.t.
NMDA injection. As shown in Figure 3A, PrP
C-/- mice
exhibited a significantly higher nociceptive response
Figure 2 Nociceptive response of PrP
+/+ and PrP
-/- mice under acute stimulation. Nociceptive response of wild type or PrP
c null mice in
the first (panel A) and second (panel B) phases of formalin-induced (0.7% or 1.25%) nociception. C, D Effect of pretreatment of animals with MK-
801 (3 nmol/i.t.) for the first (panel C) and second (panel D) phases of the formalin response. E. Nociceptive responses of WT and null mice
following intraplantar injection of glutamate. Each column represents the mean ± S.E.M. (n = 6-9). *P < 0.05, ***P < 0.001.
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intrathecally delivered NMDA. Interestingly, intrathe-
cal injection of the lower dose of NMDA (30 pmol),
which did not appear to affect wild-type mice,
increased licking/biting time in PrP
C-/- null mice.
These data suggest that hyperactivity of spinal NMDA
receptors of PrP
C null mice may account for the
decreased nociceptive sensitivity observed for those
animals. As expected, treatment of animals with MK-
801 (0.005 mg/kg, i.p., 30 minutes prior) prevented
the effects of NMDA (Figure 3B).




To determine if PrP
C modulates pain signalling under
neuropathic conditions, we examined the response of
wild type and null mice after sciatic nerve ligation
(Chronic Constriction Injury-CCI). As shown in Figure
4, sciatic nerve ligation triggered decrease mechanical
(Figure 4A) and thermal (Figure 4B) withdrawal thresh-
olds in wild-type mice. Strikingly, this treatment did not
further augment the already increased sensitivity of null
mice to thermal and mechanical stimuli, as if PrP
C-/-
mice behave as if they were tonically neuropathic. More-
over, treatment with MK-801 (3 nmol/i.t.) completely
reversed mechanical allodynia induced by CCI in wild
type mice and at least partially reversed the reduced
mechanical threshold in nerve ligated PrP
C null mice
(Figure 4C). A three-way analysis of variance revealed a
statistical difference between genotype [F(3,4) = 9.13, P
< 0.05], genotype X-treatment interaction [F(1,07) = 4.7,
P < 0.01] and genotype × treatment × nerve injured
interactions [F(1,75) = 11.4, P < 0.05].
Discussion
It is well established that glutamate is involved in noci-
ceptive processing in the spinal cord in both normal
conditions and under certain pathological nociceptive
processes [4,11,17] with NMDA receptors being the a
key player in the binding of glutamate and activation of
postsynaptic responses [18]. Under conditions of neuro-
pathic pain, NMDA receptors are upregulated to med-
iate sensitization in second order neurons give rise to a
phenomenon termed “wind up” [19-22] leading to allo-
dynia and hyperalgesia [5]. Consequently, NMDA recep-
tor antagonists have been known to decrease neuronal
hyperexitability and reduce pain, and the efficacy of sev-
eral NMDA receptor antagonists has been investigated
in preclinical [8,9,23] and clinical pain studies [10]. Con-
versely, processes that augment NMDA receptor func-
tion would be expected to be pronociceptive.
We have recently shown that PrP
C physically interacts
with NMDA receptors to inhibit NMDA receptor activ-
i t yi nt h eb r a i n[ 1 5 ] .T h ea b s e n c eo fP r P
C resulted in
increased amplitudes and durations of synaptic NMDA
currents [15] whereas AMPA receptors were unaffected
[24]. The data presented here are consistent with a simi-
lar NMDA receptor hyperfunction in the afferent pain
pathway. Mice lacking PrP
c displayed increased nocicep-
tive responses in thermal and mechanical tests, and
showed an increased susceptibility to the development
of inflammatory pain. Of note, an intrathecal dose of
NMDA (30 pmol/i.t.), which does not induce in wild-
type animals any pain behaviour per se, produced noci-
ceptive behaviour in PrP
C null mice that was compar-
able to that exhibited by wild-type animals injected with
a 10 fold higher dose of NMDA (300 pmol/i.t.). These
data fit with NMDA receptor hyperactivity, and suggest
that PrP
C null mice behave as if they are in a basal neu-
ropathic pain state.
It is well established that nociceptive behaviour
observed during first phase of formalin pain is a result
of the direct chemical activation of peripheral
Figure 3 Nociceptive response of PrP
+/+ and PrP
-/- mice in
response to NMDA treatment. (A) Nociceptive response of wild
type or PrP
c null mice following intrathecal injection of NMDA (30
pmol/i.t. or 300 pmol/i.t.). Each column represents the mean + S.E.
M. (n = 5-6). *P < 0.05. (B) Effect of MK-801 on the pain behaviour
induced by intrathecal injection of NMDA (30 pmol). Each column
represents the mean ± S.E.M. Control data (hatched bars) were
obtained following i.t. injection of 5 μl PBS (i.e., the same route of
delivery as for NMDA). NMDA data were obtained either following i.
p. injection of 10 ml/kg PBS (black bars) or 0.005 mg/kg MK-801
(white bars). In this case, PBS serves as a control for MK-801. (n = 6-
9). *P < 0.05, **P < 0.01.
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primary afferent, whereas the second phase results from
central sensitization of dorsal horn neurons induced by
primary afferent activity and peripheral inflammatory
response [25]. However, the nociception caused by
intraplnatar (i.pl.) injection of glutamate involves periph-
eral, spinal and supraspinal sites of action and is greatly
mediated by both NMDA and non-NMDA receptors as
well as by the release of nitric oxide [26]. Furthermore,
it is also mediated by capsaicin-sensitive fibres and by
release of neurokinins from sensory neurons that acti-
vate NK2 and B1 receptors [27]. NMDA receptor
antagonists are effective in attenuating both phases of
the nociception induced by formalin in rodents when
delivered systemically [28,29] or spinally [30,31]. More-
over, NMDA receptor inhibitors reduced windup in dor-
sal horn neurons in animals with peripheral nerve injury
[32-34], and NMDA receptor inhibition may impair
wind-up in spinal neurons that relay C fiber input to
the primary somatosensory cortex [35]. Our data show-
ing sensitivity of the all of the observed PrP
C null
mouse pain phenotypes to NMDA receptor blockers
thus fit with these previous studies. Also in agreement
with our data are results from Meotti and co-workers
[36] showing that PrP
C null mice exhibited higher num-
ber of abdominal constrictions following intraperitoneal
acetic acid injection when compared to wild-type mice.
On the other hand, the same study showed that PrP
C
null mice appeared to exhibit less pain in the tail-flick
test, and had no difference in latency response in the
hot-plate test, in contrast with our findings.
Although much attention has been focused on the
infectious (misfolded) scrapie form of PrP
C (termed
PrP
Sc) it is becoming increasingly evident that normal
PrP
C plays an important role in the normal physiology of
the nervous system [37]. This includes neuroprotection
Figure 4 Nociceptive response of PrP
+/+ and PrP
-/- mice under neuropathic pain conditions. Mechanical (panel A) and thermal (panel B)
withdrawal threshold of wild type or PrP
c null mice after CCI-induced neuropathy. The control data were obtained from sham-operated animals.
(C) Effect of pretreatment of animals with MK-801 (3 nmol/i.t.) on mechanical withdrawal threshold. Each point or column represents the mean
± S.E.M. (n = 6-12). *P < 0.05, **P < 0.01, ***P < 0.001.
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from development of depressive like behaviour [16] all of
which have been linked to NMDA receptors. Our find-
ings showing increased pain in PrP
C null mice fit with
the concept of PrP
C playing a beneficial physiological
role. It is widely recognized that misfolding of PrP
C into
a b-sheet rich infectious prion mediates severe neurologi-
cal phenotypes, such as Creutzfeldt-Jakob disease (CJD)
and variant CJD [41-43]. In these disorders, normal PrP
C
is progressively converted into infectious prions, which
then form plaques and cause severe neurodegeneration,
ultimately leading to death. It is possible that the conver-
sion of normal PrP
C results in altered NMDA receptor
currents in these patients, either by a reduction in the
levels of normal PrP
C, or by binding of misfolded PrP
Sc
to the receptor complex. Such a mechanism may indeed
fit with data showing that neuronal cultures infected with
PrP
Sc are protected from cell death by NMDA receptor
blockers [44]. In this context, it is interesting to note that
a substantial fraction of new variant CJD patients show
increased pain sensitivity [45] including limb pain [46].
Furthermore, there is a case report of a woman who
developed vulvodynia despite normal vulvo-vaginal
examination, and this patient was subsequently diag-
nosed with CJD [47]. While it is unknown as to whether
this is due to augmentation of spinal NMDA receptor
function in these patients due to compromised PrP
C reg-
ulation of the receptors, such a mechanism would be
consistent with our observations in mice.
Conclusion
In summary, our data indentify PrP
C as an important
negative regulator of pain signalling. Considering that
PrP
C physically interacts with the receptor complex to
depress current amplitude, it may perhaps be possible to
mimic this inhibition with small organic molecules
interacting at the PrP
C interaction site on the receptor.
Materials and methods
Animals
All experiments were conducted following the protocol
approved by the Institutional Animal Care and Use
Committee (protocol #M09100) and all efforts were
made to minimize animal suffering. Unless stated other-
wise, 10 week old male mice (C57BL/6J wild type and
PrP null weighing 25-30 g) were used. Animals were
housed at a maximum of five per cage (30 × 20 × 15
cm) with food and water ad libitum.T h e yw e r ek e p ti n
12 h light/dark cycles (lights on at 7:00 a.m.) at a tem-
perature of 23 ± 1°C. All manipulations were carried out
between 11.00 am and 3:00 pm. Different cohorts of
mice were used for each test and each mouse was used
only once. The observer was blind to the experimental
conditions in the experiment examining the age
dependence of the pain phenotype. Mice with a targeted
disruption of the prion gene (PrP) of the Zürich 1 strain
[48] were obtained from the European Mouse Mutant
Archive (EM:0158; European Mouse Mutant Archive,
Rome) and out-bred to generate PrP
-/- (PrP-null) litter-
mates used in the experiments. Genotyping was per-
formed by gel electrophoresis of PCR products obtained
from genomic DNA that was isolated from tail samples.
Primers and PCR parameters were similar to those used
previously [48].
Drugs and treatment
The following drugs were used in the study: L-glutamic
acid hydrochloride, MK-801, N-methyl-D-aspartatic
acid, Formaldehyde (Sigma Chemical Company, St.
Louis, MO, USA). All drugs were dissolved in PBS.
When drugs were delivered by the intraperitoneal (i.p.)
route, a constant volume of 10 ml/kg body weight was
injected. When drugs were administered by the
intrathecal (i.t.) route, volumes of 5 μl were injected.
Appropriate vehicle-treated groups were also assessed
simultaneously. The choice of the doses of each drug
was based on preliminary experiments in our
laboratory.
Formalin test
The formalin test is a widely used model that allows us
to evaluate two different types of pain: neurogenic pain
is caused by direct activation of nociceptive nerve term-
inals, while the inflammatory pain phase is mediated by
a combination of peripheral input and spinal cord sensi-
tization [49-51]. Animals received 20 μl of different con-
centrations of formalin solution (1.25% or 2.5%) made
up in PBS injected intraplantarly (i.pl.) in the ventral
surface of the right hindpaw. We observed animals indi-
vidually from 0-5 min (neurogenic phase) and 15-30
min (inflammatory phase). Following i.pl. injection of
formalin, the animals were immediately placed individu-
ally in observation chambers and the time spent licking
or biting the injected paw was recorded with a chron-
ometer and considered as nociceptive response. In
experiemnts involving MK-801, mice were treated by
intrathecal delivery 10 minutes prior to formalin injec-
tion (1.25%) at a dose of 3 nmol.
Intraplantar glutamate injection
The procedure used was similar to that described pre-
v i o u s l y[ 2 6 ] .B r i e f l y ,av o l u m eo f2 0μl of glutamate (3
nmol/paw or 10 nmol/paw prepared in PBS) was
injected i.pl. into the ventral surface of the right hind-
paw. Animals were observed individually for 15 min fol-
lowing glutamate injection. The amount of time spent
licking the injected paw was recorded with a chron-
ometer and was considered as nociceptive response.
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To directly investigate the role of spinal glutamate
receptors in the nociceptive behaviour observed for PrP
c
knockout mice, we compared the nociceptive behavior
of wild-type and PrP
c knockout mice after a single
intrathecal injection of NMDA. Animals received an i.t.
injection of 5 μl of NMDA solution. Injections were
given to non-anaesthetized animals using the method
described by Hylden and Wilcox [52]. Briefly, animals
were restrained manually and a 30-gauge needle
attached to a 25-μl microsyringe was inserted through
the skin and between the vertebrae into the subdural
space of the L5-L6 spinal segments. NMDA injections
(30 pmol or 300 pmol) were given over a period of 5
seconds. The amount of time th a ta n i m a l ss p e n tb i t i n g
or licking their hind paws, tail or abdomen was deter-
mined with a chronometer and considered as nocicep-
tive response. In experiments involving MK-801, mice
were treated by intraperitoneal delivery 30 minutes prior
to NMDA injection at a dose of 30 pmol/site.
Chronic constriction injury (CCI)-induced neuropathy
For neuropathic pain, we used a sciatic nerve injury
model according to the method described by Bennett
and Xie [53] with minor modifications. Briefly, mice
were anaesthetized (isoflurane 5% indution, 2.5% main-
tenence) and the right sciatic nerve was exposed at the
level of the thigh by blunt dissection through the biceps
femoris. Proximal to the sciatic nerve trifurcation, about
12 mm of nerve was freed of adhering tissue and 3
loose ligatures (silk suture 6-0) were loosely tied around
it with about 1 mm spacing so that the epineural circu-
lation was preserved. In sham-operated rats, the nerve
was exposed but not injuried. Mechanical and thermal
withdrawal thresholds were determined 3 days after sur-
gery. In another series of experiments, PrP
C null mice
received MK-801 (3 pmol/i.t.) and mechanical withdra-
wal threshold was evaluated 10 min after drug delivery.
Mechanical withdrawal threshold
To assess changes in sensation or in the development of
mechanical allodynia, sensitivity to tactile stimulation
was measured using the DPA (Ugo Basile, Varese, Italy).
Animals were placed individually in a small enclosed
testing arena (20 cm × 18.5 cm × 13 cm, length × width
× height) with a wire mesh floor for 60 min. The DPA
device was positioned beneath the animal, so that the
filament was directly under the plantar surface of the
foot to be tested. Each paw was tested three times per
session. For experiment 1, the same cohort of both
wild-type and PrP
C null mice were tested at age 1, 2, 3,
4 and 5 months. For neuropathic pain, testing was per-
formed on the ispsilateral (ligated) paw before ligation
(day 0) and then on the 3
rd day after ligation.
Thermal withdrawal threshold
Thermal hyperalgesia was examined by measuring the
latency to withdrawal of the hind paws from a focused
beam of radiant heat applied to the plantar surface
using a Plantar Test apparatus (Ugo Basile). Three trials
each for the right hind paws were performed and for
each reading, the apparatus was set at a cut-off time of
20 s. As with mechanical pain testing, the same cohorts
of either wild-type or PrP
C null mice were used at 1, 2,
3 ,4a n d5m o n t h s .T h e r m a lw i t h d r a w a lt h r e s h o l dw a s
tested 1 day after they were used for mechanical testing.
For neuropathic pain, testing was performed on the isp-
silateral (ligated) paw before ligation (day 0) and then
on the 4
th day after nerve injury.
Statistical analysis
Data were presented as means ± SEM and evaluated by
t-tests, two-way or three-way analysis of variance
(ANOVA) followed by Tukey test when appropriate. A
value of P < 0.05 was considered to be significant.
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